Health

Oncotelic Therapeutics Highlights PeerReviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients

Data support further evaluation of investigational antisense OT‑101 (trabedersen) as a TGFB2‑targeted approach in pancreatic ductal adenocarcinoma (PDAC). AGOURA HILLS,…

GlobeNews Wire

React19 Launches This Is Our Shot Campaign as U.S. Vaccine Injury Victims Continue to Go Unheard and Uncompensated

SALT LAKE CITY, Nov. 06, 2025 (GLOBE NEWSWIRE) -- As the federal government’s Countermeasures Injury Compensation Program (CICP) has approved…

GlobeNews Wire

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry validates condensate modulator…

GlobeNews Wire
- Advertisement -
Latest Health News

EmPRO Reports Another Year of Strong Financial Results with Significant Growth in Net Income and Surplus During 2025

ROSLYN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- EmPRO Insurance Company (EmPRO),…

GlobeNews Wire

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 09:00 ET  | Source: Senti Biosciences, Inc. SOUTH SAN…

GlobeNews Wire

Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Ricas Coyol Free Trade Zone

BROOKLYN PARK, MN, April 13, 2026 (GLOBE NEWSWIRE) -- Switchback Medical, a…

GlobeNews Wire

Glo & Spa-rkle Aesthetics and Medical Spa Unveils New State-of-the-Art Location in Lubbock, Texas

Join the Grand Opening Celebration on May 1, 2026, for an Evening…

GlobeNews Wire

Pelthos Therapeutics Announces CFO Transition

Senior Vice President, Finance & Accounting John M. Gay named Chief Financial…

GlobeNews Wire

BioNTech and DualityBios Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint…

GlobeNews Wire